Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers


The solution


Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers.
We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.


News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

Gate2Brain and Intact Barrier Brain Tumors: A Ray of Hope in the Fight against DIPG

On the occasion of World Brain Day Meritxell Teixidó, CEO & CSO of Gate2Brain, analyzes the scientific…

Alejandro Sosnik – Meet the Team

Recently, a new member joined our team. We're so grateful to have such an awesome crew!!. It’s a pleasure…

Meritxell Teixidó, Entrepreneurial Advisory Board member of The Peptide Drug Hunting Consortium

We are thrilled to announce that our CEO, Meritxell Teixido, has been appointed as a new member…

Winner of the Innovator’s Pitch Challenge Award at RESI Europe 2024

At Gate2Brain, we are thrilled to announce that we have been granted the Innovator's Pitch Challenge…

Fortifying CDMO Partnerships Elevating GMP Protocols

Gate2Brain's recent journey to India was transformative, significantly enhancing our collaboration with…

PhD Day 2024:”Beyond the Thesis: Bridging Academia and Industry”

On May 31st, our CEO, Meritxell Teixidó, participated in PhD Day 2024, themed "Beyond the Thesis: Bridging…

Andrés Morales La Madrid – Meet the Team

, ,
Recently, a new member joined our team. We're so grateful to have such an awesome crew!! It’s a pleasure…


At Gate2Brain, we are thrilled to participate in the upcoming edition of the RESI Europe Innovator’s…

Impuls Biomedicine – IRB

The Barcelona Institute for Research in Biomedicine recently released a video highlighting Gate2Brain…

Making therapies a reality for patients by addressing unmet medical needs.


Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain